Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68


Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F.

Clin Cancer Res. 2016 Nov 3. doi: 10.1158/1078-0432.CCR-15-2620. [Epub ahead of print]


Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.

Clin Cancer Res. 2017 Apr 15;23(8):1981-1987. doi: 10.1158/1078-0432.CCR-16-0235. Epub 2016 Oct 3.


A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2016 Sep;174(6):991-3. doi: 10.1111/bjh.13830. Epub 2015 Nov 16. No abstract available.


Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B.

Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.


The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.


Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD Jr, Barlogie B.

Leukemia. 2015 May;29(5):1195-201. doi: 10.1038/leu.2015.15. Epub 2012 Feb 2.


CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S.

Blood. 2014 Sep 25;124(13):2051-60. doi: 10.1182/blood-2014-02-555813. Epub 2014 Jul 24.


Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D Jr, Barlogie B, Usmani SZ.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):211-4. doi: 10.1016/j.clml.2013.11.004. Epub 2013 Nov 16.


Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.

Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M.

Leukemia. 2014 Apr;28(4):888-93. doi: 10.1038/leu.2013.214. Epub 2013 Jul 15.


Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B.

Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19.


Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.

Blood. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. Epub 2013 Jan 10.


Prognostic implications of cumulative dosing in total therapy 3.

Barlogie B, Crowley J.

Blood. 2012 Oct 18;120(16):3383-5. doi: 10.1182/blood-2012-05-426809. No abstract available. Erratum in: Blood. 2013 Mar 7;121(10):1924.


Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B.

Haematologica. 2013 Jan;98(1):71-8. doi: 10.3324/haematol.2012.066555. Epub 2012 Jun 24.


Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.


Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.

Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, Waheed S, Shaughnessy JD Jr, Alsayed Y, Heuck CJ, van Rhee F, Milner T, Hoering A, Szymonifka J, Sexton R, Sawyer J, Singh Z, Crowley J, Barlogie B.

Leukemia. 2012 Nov;26(11):2398-405. doi: 10.1038/leu.2012.107. Epub 2012 Apr 17.


Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.

Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.

Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.


Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.


International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13. Erratum in: Cancer. 2011 Jul 1;117(13):3060.


Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B.

Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25.


Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A, Petty N, Crowley J.

J Clin Oncol. 2010 Jun 20;28(18):3023-7. doi: 10.1200/JCO.2009.26.4465. Epub 2010 May 17.

Supplemental Content

Loading ...
Support Center